Inhaled magnesium sulfate in the treatment of acute asthma (Review)
Blitz
Objectives
To examine the efficacy of inhaled MgSO 4 in the treatment asthma exacerbations.
Search strategy
Randomised controlled trials were identified from the Cochrane Airways Group "Asthma and Wheez*" register. These trials were supplemented with trials found in the reference list of published studies, studies found using extensive electronic search techniques, as well as a review of the gray literature and conference proceedings.
Selection criteria
Randomised (or pseudo-randomised) controlled trials were eligible for inclusion. Studies were included if patients were treated with nebulised MgSO 4 alone or in combination with β 2 -agonist and where compared to β 2 -agonist alone or inactive control.
Data collection and analysis
Trial selection, data extraction and methodological quality were assessed by two independent reviewers. Efforts were made to collect missing data from authors. Results from fixed effects models are presented as standardized mean differences (SMD) for pulmonary functions and relative risks (RR) for hospital admission; both are displayed with their 95% confidence intervals (95% CI).
Main results
Six trials involving 296 patients were included. Four studies compared nebulised MgSO 4 with β 2 -agonist to β 2 -agonist and two studies compared MgSO 4 to β 2 -agonist alone. Three studies enrolled only adults and 2 enrolled exclusively pediatric patients; three of the studies enrolled severe asthmatics. Overall, there was a non significant improvement in pulmonary function between patients whose treatments included nebulised MgSO 4 in addition to β 2 -agonist (SMD: 0.23; 95% CI: -0.03 to 0.50; 4 studies). Hospitalizations were similar between the groups (RR: 0.69; 95% CI: 0.42 to 1.12; 3 studies). Subgroup analyses did not demonstrate significant differences in lung function improvement between adults and children, but in severe asthmatics the lung function difference was significant (SMD: 0.55; 95% CI: 0.12 to 0.98). Conclusions regarding treatment with nebulised MgSO 4 alone are difficult to draw due to lack of studies in this area.
Authors' conclusions
Nebulised inhaled magnesium sulfate in addition to β 2 -agonist in the treatment of an acute asthma exacerbation, appears to have benefits with respect to improved pulmonary function in patients with severe asthma and there is a trend towards benefit in hospital admission. Heterogeneity between trials included in this review precludes a more definitive conclusion.
P L A I N L A N G U A G E S U M M A R Y
Acute asthma is a common emergency department problem usually treated with systemic corticosteroids, inhaled beta-agonists and a variety of other agents (including inhaled corticosteroids, inhaled anticholinergics, intravenous magnesium, oxygen, etc). Intravenous magnesium sulfate has demonstrated efficacy in acute severe asthma and this review identified evidence to demonstrate that using inhaled magnesium sulfate combined with a beta-2-agonist (β 2 -agonist) for an acute asthma exacerbation provides beneficial effects with respect to improved pulmonary function. The evidence, however, that nebulised magnesium sulfate positively impacts the clinically more important outcomes, such as hospital admissions, are lacking.
B A C K G R O U N D
Asthma is a chronic respiratory disease that is characterized by periods of relative control and episodes of deterioration referred to as exacerbations. Exacerbations range in severity from mild to status asthmaticus and can result in visits to health care providers, emergency departments, and may at times require hospitalisations. While rare, intubations, admissions to the intensive care setting and deaths from severe acute asthma do still occur. In most people, even though the serious consequences are avoided, the prevention and treatment of asthma exacerbations are an important consideration of their disease. Due to this impact on lifestyle, the costs to the patient and the health care system, and the mortality, asthma is responsible for significant personal and social burden.
Acute episodes of bronchoconstriction caused by airway inflammation are a hallmark of the exacerbation. These episodes generally result in increased requirements for inhaled beta-2-agonist (β 2 -agonist) therapy. Unfortunately, in acute asthmatic episodes, this is often not enough to relieve the bronchospasm and reduce dyspnoea. The shortcomings of β 2 -agonist therapy have resulted in the use of a variety of other treatments in the management of acute asthma. For example, evidence suggests systemic corticosteroids (Rowe 1992) Magnesium sulfate (MgSO 4 ) is an agent that has been proposed as a possible additive treatment in acute asthma, and recently has been shown to be effective in severe acute asthma when delivered parenterally (Rowe 2004) . Magnesium may be effective in acute asthma through one or more of a variety of mechanisms. Magnesium has been shown to relax smooth muscle, and may be involved with inhibition of smooth muscle contraction. This theory has been proposed as an explanation for the effects of MgSO 4 in acute asthma; however, this explanation may be too simplistic. Magnesium is also involved with cellular homeostasis through its role as an enzymatic cofactor, as well as being involved in acetylcholine and histamine release, from cholinergic nerve terminals and mast cells, respectively. Recently, investigators have proposed that the effect of MgSO 4 is related to its ability to block the calcium ion influx to the smooth muscles of the respiratory system (Gourgoulianis 2001) . Finally, the role of MgSO 4 as an anti-inflammatory has been identified in adult asthmatics (Cairns 1996) .
The potential clinical benefits of inhaled MgSO 4 have been studied and research publications have produced conflicting results. Consequently, this agent is not currently recommended as part of the current guidelines and has not been used widely in most acute care settings. Until now, there has been no attempt made to examine this effect in a systematic fashion. This systematic review is designed to examine this question and provide a summary estimate of the effect (or lack thereof ) of aerosolized MgSO 4 in the treatment of acute asthma.
O B J E C T I V E S
The objective of this review is to determine the efficacy of inhaled MgSO 4 administered in acute asthma on pulmonary functions and admissions.
Specific aims
To quantify the effects of inhaled MgSO 4 alone or in combination with inhaled β 2 -agonist compared to inhaled β 2 -agonist alone or placebo. Specific outcomes include:
(1) pulmonary function (forced expiratory volume in one second {FEV-1}, peak expiratory flow rate {PEFR} and their respect % predicted {% FEV-1, % PEFR}); (2) admission to hospital; (3) vital signs (pulse and respiratory rates; systolic and diastolic blood pressure); (4) side effects (tremor, nausea, etc).
C R I T E R I A F O R C O N S I D E R I N G S T U D I E S F O R T H I S R E V I E W

Types of studies
Randomised (or quasi-randomised) controlled trials were considered for inclusion.
Types of participants
Only studies restricting enrolment to patients with acute asthma were considered; patients with chronic or "stable" asthma were excluded from the review. Studies involving all ages were considered for inclusion; where possible, the data were categorized into 2-16 years old (pediatric) and > 16 years old (adult). Asthma was defined using several accepted clinical and guideline-based criteria.
Types of intervention
Studies were considered for inclusion if participants were randomised to receive inhaled MgSO 4 and compared to a control treatment. That is, studies comparing the efficacy of aerosolized MgSO 4 and β 2 -agonist versus β 2 -agonist alone or inhaled MgSO 4 versus β 2 -agonist were included. Co-interventions were permitted, and information pertaining to co-interventions received was recorded. Whenever these data were not available, a request was sent to the study authors.
Types of outcome measures
Primary outcome was defined as the change in pulmonary function testing from baseline. Secondary outcomes considered were clinical severity scores, proportion of patients requiring admission, duration of symptoms, vital signs and side effects.
S E A R C H M E T H O D S F O R I D E N T I F I C A T I O N O F S T U D I E S
See: Airways Group methods used in reviews.
See: Collaborative Airways Group search strategy. The Cochrane Airways Groups "Asthma and Wheez* RCT" register was searched for the following terms: magnesium OR MgSO4 OR Mg OR MS OR magnesium sulfate or magnesium sulphate. The results of this search were screened to omit studies that clearly involved only intravenous or parenteral administration of magnesium.
In addition, searches were also conducted on the following computerized bibliographic databases: MEDLINE (1966-present) , EMBASE (1988 to present) , LILACS, Cochrane Clinical Trials Registry, Web of Science and Dissertation Abstracts. The reference lists of all selected articles, primary studies and review articles were examined for relevant studies. Primary authors were contacted for information on additional trials (published and unpublished). Clinicians, colleagues, collaborators and trialists were contacted to identify potentially relevant studies. Since this agent is not currently commercially delivered, no industry sponsor was contacted.
M E T H O D S O F T H E R E V I E W
STUDY SELECTION
The selection of studies involved two steps. First, to retrieve studies, the initial search of all databases and reference lists was screened by title, abstract, MeSH Headings and keywords by two independent investigators (MB, BD) to identify all citations that are RCT's or possible RCT's with potential relevance. The full text of those selected articles was obtained for formal inclusion review. Second, another reviewer (BHR) independently decided on trial inclusion using pre-determined eligibility criteria.
ASSESSMENT OF QUALITY Assessments of quality were completed independently by two reviewers. First, using the Cochrane approach to assessment of allocation concealment (Schulz 1995) , all trials were scored using the following scale: Grade A: Adequate concealment Grade B: Uncertain Grade C: Clearly inadequate concealment Each study was also evaluated using the previously validated Jadad 5-point scale to assess randomisation, double blinding, and withdrawals and dropouts (Jadad 1996) according to the following criteria: 1) Was the study described as randomised (1=yes; 0=no)?; 2) Was the study described as double-blind (1=yes; 0=no)?; 3) Was there a description of withdrawals and dropouts (1=yes; 0=no)?; 4) Was the method of randomizations well described and appropriate (1=yes; 0=no)?; 5) Was the method of double blinding well described and appropriate (1=yes; 0=no)?; 6) Deduct 1 point if methods for randomizations OR blinding were inappropriate.
In addition, whether the study used intention-to-treat analysis was recorded along with source(s) of funding.
DATA EXTRACTION Data were extracted independently by two reviewers (MB, BD) using a standardized collection form. The following information was extracted if available: characteristics of the study (design, methods of randomisation, withdrawals / dropouts); participants (age, gender); intervention (type, dose, route of administration, timing and duration of therapy, co-interventions); control (agent and dose); outcomes (types of outcome measures, timing of outcomes, adverse events); and results. Unpublished data were requested from the primary authors when necessary.
DATA ANALYSIS
All data was entered into RevMan (Cochrane Collaboration, Version 4.2.7) by a single reviewer (SB). MetaView was used to combine trial data.
For dichotomous variables, both individual and pooled statistics are expressed as relative risk (RR) with 95% confidence intervals (CI). For continuous data, individual data was reported as standardized mean differences (SMD) with 95% CIs. Results were calculated using both fixed and random effects models.
We tested for heterogeneity with significance set at <0.10 using the Breslow-Day test. Possible sources of heterogeneity were assessed by subgroup and sensitivity analyses. A priori subgroup analyses were planned to examine the effect of: (1) age (pediatric, adult); (2) severity of asthma as measured by pre-administration spirometric deviation from predicted (baseline FEV1 or PEF <50% predicted).
Sensitivity analyses were planned to assess the effect of: (1) methodological quality of included trials; and (2) intention-to-treat status.
We also planned to test for publication bias using the funnel plot visually and quantitatively (i.e. the rank correlation test and / or the graphical test with or without heterogeneity) depending on the number of trials included in the review.
D E S C R I P T I O N O F S T U D I E S
General
Six trials, which included 296 patients, were incorporated into the review (see Characteristics of Included Studies). All of the studies included in this manuscript were published since 1995. There is no particular geographic preference with the U.S., India, New Zealand, Turkey, and Argentina all being represented. There was no previous review that focused on this issue. The few times that inhaled magnesium has been mentioned, it has been as (a minor) part of larger reviews (Harari 1998).
Populations Three of the six included studies involved adults exclusively (Bessmertny 2002; Hughes 2003; Nannini Jr 2000) and one included adults and pediatric patients (Mangat 1998). The remaining 2 studies enrolled pediatric patients (Mahajan 2004; Meral 1996) . Subgroup analyses on the pediatric and adult populations were completed.
The severity of disease varied between studies. Two studies (Hughes 2003 , Mangat 1998 had specific lung function criteria, while the other 4 studies enrolled patients previously diagnosed with asthma using accepted clinical standards. Based on the baseline demographic data, three studies (Hughes 2003; Mangat 1998; Nannini Jr 2000) were considered to enrol severe asthmatics (FEV-1 or PEF < 50% predicted at baseline). Subgroup analyses on the severe and moderate asthmatic populations were completed.
Five studies enrolled patients presenting to the emergency department. Only one study (Meral 1996) stated that patients were randomised during "asthma attacks". Two studies (Mangat 1998; Meral 1996) excluded patients who had taken asthma medication within the last 12 hours. A third (Nannini Jr 2000) excluded patients who had received oral or parenteral corticosteroids in the last seven days. The most recent study (Mahajan 2004) excluded patients who had received steroids, theophylline or ipratropium bromide within 3 days of presenting to the ED.
Interventions
All studies used nebulised β 2 -agonist (with or without normal saline) as the control treatment; however, the total dose varied depending on the number of nebulizations. When the information was available, most included studies used MgSO 4 of similar concentration but dose per nebulization and the number of nebulizations varied. All but two studies (Mangat 1998; Meral 1996) described the MgSO 4 solution as either isotonic or isosmolar with pleural fluid. The magnesium was uniformly delivered via a nebuliser rather than metered dose inhaler. All studies used a control that was similar in appearance to the treatment drug and is most often described as saline. One study (Hughes 2003) collected data on patients' ability to distinguish between the treatment and control, and noted no ability to discern. Even when not expressly stated, it can reasonably be assumed that the control (placebo) would be similar in appearance to the treatment drug (especially if given in a β 2 -agonist vehicle).
Four studies (Bessmertny 2002; Hughes 2003; Mahajan 2004 ; Nannini Jr 2000) compared β 2 -agonist with MgSO 4 to β 2 -agonist with placebo (normal saline), while two studies (Mangat 1998; Meral 1996) compared MgSO 4 to β 2 -agonist. The results of this review are reported for pulmonary functions, hospital admissions and side effects based on the two intervention types (β 2 -agonist with MgSO 4 or MgSO 4 alone vs β 2 -agonist alone).
Co-interventions Co-interventions used added complexity and heterogeneity to the studies. In three studies (Hughes 2003; Mangat 1998; Mahajan 2004) , systemic corticosteroids were administered to all patients, although the timing (before/after nebulised treatment) varied. In one study, systemic corticosteroids were administered if there was no improvement after the 3 doses of study treatment (Bessmertny 2002) . Outcomes All studies report results from pulmonary function tests as an outcome; however, one study (Meral 1996) reported lung function outcome data as a relative change from baseline. As it was not appropriate to combine these data with the other studies (which are not reporting lung function results as a change from baseline), data from this study are not currently included in the pooled analysis. Attempts to secure the end-of study data have failed so far.
Four studies (Hughes 2003; Mangat 1998; Mahajan 2004; Nannini Jr 2000) also report admission to hospital as an outcome. All studies mentioned serious adverse events; however, the details regarding mild to moderate adverse events were sparse.
None of the studies reported a specific clinical severity score or duration of symptoms. Most studies reported vital signs at baseline but not at follow-up. These outcomes were not investigated in the systematic review.
Pending Assessments The status of one study (Wijetunge 2002) referenced in a clinical trials register reportedly compared nebulized MgSO 4 with placebo in addition to conventional bronchodilator treatment is unknown. The primary authors for this study and the included study (Meral 1996) for which the lung function data is not included in the pooled analysis have been contacted to determine if pertinent data from their studies are available and suitable for inclusion in this review. These studies will be included in updates of this review should information become available.
M E T H O D O L O G I C A L Q U A L I T Y
Overall, the methodological quality of the included studies was uniformly high. All studies were randomised and placebo controlled. Only one investigator did not explicitly state that the study was double blinded. All included studies used intention-to-treat analyses, therefore the planned sensitivity analysis to determine the effect of intention-to-treat status was not required. All but one study (Meral 1996) scored 3 on the Jadad scale as none of the investigators explicitly mentioned their methods for randomisation or double-blinding. Due to lack of information provided, all studies rated a B in concealment of allocation.
Due to the small number of studies included and the relative size of each the planned tests for publication bias were not carried out.
R E S U L T S
Computerized Search
The initial search yielded 145 references that were at least potentially relevant controlled trials. Two additional references were identified from bibliographic searching of relevant studies. The author for one study that was originally identified as an abstract was contacted and the conditionally accepted paper was provided to the reviewers for data extraction.
This review is considered to be up to date as of January 2004.
Pulmonary Function Tests
Most studies did not report change in pulmonary function and pooled results from all studies failed to identify a difference in baseline pulmonary function between the treatment and control groups. There was variation in the specific pulmonary function measure reported (% predicted PEF or FEV-1 and raw PEF or FEV-1) as well as the time after treatment when pulmonary functions were recorded; two studies reported pulmonary function measures only up to 20 minutes after treatment. For these reasons the results are reported using fixed effects, standardized mean difference in pulmonary function measured at or before 60 minutes after treatment. Based on the studies that measured pulmonary functions for longer durations, we noted that the largest change in pulmonary function appeared to be early after treatment. Consequently, we were satisfied grouping the 20 minute and 60 minute pulmonary function test results as the outcome of interest.
MgSO 4 with β 2 -agonist compared to β 2 -agonist alone: Pulmonary functions were improved when MgSO 4 with β 2 -agonist was compared to β 2 -agonist alone (SMD: 0.23; 95% CI:-0.03 to 0.50), but there was considerable between study heterogeneity identified (I 2 = 53%; Figure 01 .01). When a random effects model was used to pool these studies the confidence interval is considerably wider (SMD 0.27, 95% CI -0.12 to 0.66). In subgroup analyses, there was no significant difference between the results from adults and those in children. In subgroup analysis, there was a significant difference in the results from the severe asthma trials (SMD 0.55, 95% 0.12 to 0.98). When compared to the the mildmoderate group this difference was not significant (SMD between groups -0.51, 95% CI -1.06 to 0.04).
MgSO 4 compared to β 2 -agonist alone: There was no evidence of an significant advantage for MgSO 4 alone compared to β 2 -agonist alone with respect to pulmonary functions (SMD: 0.17; 95% CI: -0.51 to 0.86); Meral (Meral 1996) demonstrated a significant advantage for β 2 -agonist alone compared to MgSO 4 alone. With a single trial contributing data, not additional analyses were possible.
Admission to Hospital
MgSO 4 with β 2 -agonist compared to β 2 -agonist alone: One study (Bessmertny 2002) did not report admissions to hospital and correspondence attempts with this author did not yield additional data. In the remaining studies, nebulised MgSO 4 in combination with an β 2 -agonist failed to demonstrate a clear reduction in the probability of admission compared to β 2 -agonist alone (RR: 0.69; 95% CI: 0.42 to 1.12) using a fixed-effects model ( Figure  01 .04), despite a promising trend. The non-significant advantage holds for MgSO 4 compared to β 2 -agonist for adults and severe asthma (RR: 0.62; 95% CI: 0.38 to 1.02); however, not for children or those with less severe asthma (RR: 2.00; 95% CI: 0.19 to 20.93). There was, however, no significant difference when formal sub-group testing was carried out between adults and children, or between severe and less severe asthma, and the confidence inter-vals were wide. Results were similar when random effects methods were employed.
MgSO 4 compared to β 2 -agonist alone: There was no significant difference between MgSO 4 compared to β 2 -agonists alone with respect to hospitalisations (RR: 0.50; 95% CI: 0.04 to 6.12); however, the wide confidence intervals suggest that equivalence cannot be claimed. With a single trial contributing data, not additional analyses were possible.
Adverse Events All studies report that there were no serious adverse events in either arm. The risk of serious adverse events was low in both the studies comparing MgSO 4 to β 2 -agonists (RD: 0.00; 95% CI: -0.11 to 0.11) or those comparing MgSO 4 with β 2 -agonist to β 2 -agonist alone (RD: 0.00; 95% CI: -0.03 to 0.03). The risk of less severe adverse events was low; however, it appears to be less likely in patients treated with MgSO 4 , alone (RD: -0.17; 95% CI: -0.41 to 0.06) or in combination with β 2 agonists (RD: -0.09; 95% CI: -0.24 to 0.06), although the differences did not reach statistical significance.
D I S C U S S I O N
This systematic review attempted to synthesize the best available evidence for the use of inhaled MgSO 4 in the treatment of acute asthma. From 6 randomised controlled trials involving nearly 300 patients, the results of this systematic review provide somewhat weak and conflicting conclusions. First, based on the available data it appears that nebulised MgSO 4 with or without β 2 -agonist can be safely administered to patients with acute moderatesevere asthma. Since it is readily available and inexpensive, its role in acute asthma deserves more scrutiny. Used alone, it appears to be of little advantage compared to more familiar, inexpensive β 2 -agonists in improving pulmonary function and reducing admissions. The evidence for MgSO 4 administered in combination with β 2 -agonists is more convincing. For example, there appears to be a clear additive benefit with respect to pulmonary functions, particularly in patients presenting to the ED with severe asthma, when MgSO 4 is administered in combination with β 2 -agonists. In addition, while there is no clear evidence that MgSO 4 administered in combination with β 2 -agonists reduces hospitalisations, the trend demonstrated (Figure 01 .04) suggests further research is urgently needed to answer this question.
Several interesting methodological issues were encountered during the completion of this review that deserve brief mention. The investigations in this field are limited by the heterogeneity of both treatments and outcome measures. Unfortunately, despite adequate evidence for the use of standardized approaches to acute asthma, such as systemic corticosteroids (Rowe 1992), anticholinergics (McDonald 2004; Spooner 2004) , intravenous MgSO 4 (Rowe 2004), and repeated β 2 -agonists (Cates 2004), the control groups in the included studies were surprisingly heterogeneous. A trial where systemic corticosteroids, β 2 -agonists and anticholinergics are administered to both groups and inhaled MgSO 4 or placebo is added to the treatment regimen in a double-blind manner is needed. Furthermore, there is a lack of consensus among researchers regarding the most appropriate pulmonary function outcome measure to report. The aforementioned trial should insist on both pulmonary function data as well as admission status at the conclusion of the ED treatment period.
There are several possible limitations to the study. First, there is a possibility of study selection bias. However, we employed two independent reviewers, and feel confident that the studies excluded were done so for consistent and appropriate reasons. Our search was comprehensive and has been updated, so it is unlikely that there are any published trials, which were missed.
In addition, publication bias may have influenced the result of this meta-analysis. For example, by missing unpublished negative trials we may be over-estimating the effect of magnesium treatment. However, in order to reduce bias, a comprehensive and systematic search of the published and unpublished literature for potentially relevant studies was conducted. This was followed by attempts to contact corresponding and first authors. One unpublished trial was identified and several negative trials were uncovered; however, we recognize that more of these types of trials may exist. Finally, due to the recent emergence of inhaled MgSO 4 treatment, there are possibly more small trials that have been conducted which for one reason or another remain unknown to us and unpublished. Without a central trial registry we may never find these results and in a review of this nature, made up of smaller studies, these small studies may make an important difference in our conclusions.
A U T H O R S ' C O N C L U S I O N S
Implications for practice
(1) Nebulised MgSO 4 appears to be effective and safe to administer to patients experiencing asthma exacerbations.
(2) Treatment with nebulised MgSO 4 should be considered in addition to inhaled β 2 -agonists in asthma exacerbations, particularly in those patients with more severe exacerbations.
Implications for research
(1) The role of nebulised MgSO 4 in asthma exacerbations has not been conclusively resolved by this review particularly with respect to MgSO 4 alone versus MgSO 4 with β 2 -agonists. Further research should be encouraged.
(2) In addition, studies of acute asthma should stratify patients by presenting severity of the exacerbation and specify outcomes which are clinically valid such as relapse or hospital admission and a more short term outcome such as change in pulmonary function. (3) There is a strong argument for asthma researchers to develop a consensus regarding the reporting of pulmonary function results.
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External sources of support
• Alberta Cancer Board CANADA
• Canadian Institutes of Health Research (CIHR), Ottawa (BHR) CANADA
Internal sources of support
• Department of Emergency Medicine, University of Alberta, Edmonton, AB CANADA Interventions Standard of care: salbutamol 2.5 mg nebulized x 1 or more, hydrocortisone 100 mg IV at presentation Treatment: salbutamol 2.5 mg nebule with 2.5 ml isotonic MgSO4 (250 mmol/L) q 30 min x 3. Control: salbutamol 2.5 mg nebule with 2.5 ml normal saline. q 30 min x3 Subjects were unable to distinguish solutions Outcomes Measured at baseline and after each treatment (q 30 min x 3): FEV1, %predicted FEV1, BP, heart rate, O2 saturation Requirement for admission at 90 minutes. Interventions Standard of care: all patients received supplemental oxygen. If patient condition worsened patient may receive salbutamol 2.5 mg nebulized at discretion of physician. Treatment: 0.5 ml salbutamol (2.5 mg) diluted in 3 ml isotonic MgSO4 (286 mOsm, 7.5% = 225 mg). Control: 0.5 ml salbutamol (2.5 mg) diluted in 3 mL normal saline. Administration: jet nebulized using oxygen at 10 L/min via mouthpiece until dry.
T A B L E S
Characteristics of included studies
Outcomes Measurements made at baseline, 10 minutes after treatment and 20 minutes after treatment. 
Characteristics of ongoing studies
Study Wijetunge 2002
Trial name or title A trial of nebulised magnesium sulphate versus placebo in addition to conventional bronchodilator treatment in acute asthma of moderate severity 
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